Background: The association between thiopurine methyltransferase (TPMT) deficiency and myelosuppression with azathioprine is well recognized. Two cases are presented that illustrate the very different outcomes that may occur with azathioprine in patients with TPMT deficiency, which affects 0.3-0.6% of caucasians. CASE 1: The first patient's TPMT deficiency was identified following hospitalization for pancytopenia attributed to azathioprine. CASE 2: The second patient was identified as deficient early in treatment and myelosuppression was avoided by treating with a greatly decreased dose (25 mg per week).
Conclusions: Testing for TPMT ideally should be performed in every patient commencing a thiopurine drug.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885160 | PMC |
| http://dx.doi.org/10.1111/j.1365-2125.2005.02474.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Population-Specific Distribution of Deficiency Variants and Ancestry Proportions in Ecuadorian Ethnic Groups: Towards Personalized Medicine.
Ther Clin Risk Manag
November 2023
Escuela de Enfermería, Facultad de Ciencias de la Salud, Universidad de Las Américas, Quito, Ecuador.
Purpose: Thiopurine S-methyltransferase (TPMT) is an enzyme that metabolizes purine analogs, agents used in the treatment of acute lymphoblastic leukemia. Improper drug metabolism leads to toxicity in chemotherapy patients and reduces treatment effectiveness. variants associated with reduced enzymatic activity vary across populations.
View Article and Find Full Text PDFImplications of Tioguanine Dosing in IBD Patients with a TPMT Deficiency.
Metabolites
October 2023
Department of Clinical Pharmacy, Clinical Pharmacology and Toxicology, Zuyderland Medical Centre, 6162 BG Sittard, The Netherlands.
Article Synopsis
- * A study examined IBD patients with different TPMT genotypes, finding that 10.3% were intermediate metabolizers and 0.8% were poor metabolizers, some of whom experienced adverse effects on standard dosages of tioguanine.
- * Reduced dosing strategies for those with abnormal TPMT levels led to safe long-term treatment, indicating that careful monitoring and adjusted dosages can make tioguanine an effective option for IBD patients.
Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation.
Biomed Pharmacother
December 2023
Instituto de Investigación Biosanitaria de Granada (Ibs.Granada), Granada, Spain; Hospital Pharmacy Unit. Hospital Universitario San Cecilio, Granada, Spain.
Article Synopsis
- Azathioprine is an immunosuppressive drug used for conditions like acute lymphoblastic leukemia and autoimmune disorders, with its effectiveness influenced by genetic factors such as TPMT and NUDT15 variants.
- The study investigated how adjusting azathioprine doses based on these genetic variations affects toxicity and efficacy in patients, specifically comparing those with intermediate and poor metabolizer genotypes against normal metabolizers.
- Findings indicated that patients with TPMT intermediate genotypes experienced fewer toxicity events and required fewer dose adjustments while maintaining similar treatment effectiveness as normal metabolizers, suggesting other genetic factors may also play a role in azathioprine's toxicity.
Thiopurine Methyltransferase Intermediate Metabolizer Status and Thiopurine-Associated Toxicity During Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia.
Clin Pharmacol Ther
June 2023
Department of Paediatrics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
Article Synopsis
- Genetic variations affecting the enzyme thiopurine methyltransferase (TPMT) can increase toxicity risk, especially in patients with TPMT deficiency, leading to higher TGN exposure.
- A study of 88 pediatric patients found that those with intermediate TPMT activity faced significantly more febrile neutropenia and myelotoxicity compared to those with normal activity, suggesting the need for adjusted dosing based on genetic status to lower toxicity risks.
Case Report: Multifocal EBV-Associated Diffuse Large B-Cell Lymphoma in a Patient With 6-MP Associated Lymphopenia With TPMT Deficiency.
Front Pediatr
May 2022
Pediatric Oncology, Hematology and Stem Cell Transplantation Program, University Children's Hospital Würzburg, Würzburg, Germany.
Introduction: EBV associated lymphoproliferative disorders (EBV LPD) are a known complication following solid organ or hematopoietic stem cell transplantation. The disturbance of the immune system leads to a lack of control of latent EBV-infected B-cells, as control by T-cells is mandatory to prevent uninhibited cell proliferation. EBV LPD in other settings is less frequent and etiology and pathogenesis are not completely understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!